Cargando…

An appraisal of genetic testing for prostate cancer susceptibility

Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected to improve outcomes through tailored treatments for men with advanced prostate cancer with g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finch, Amy, Clark, Roderick, Vesprini, Danny, Lorentz, Justin, Kim, Raymond H., Thain, Emily, Fleshner, Neil, Akbari, Mohammad R., Cybulski, Cezary, Narod, Steven A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217944/ https://www.ncbi.nlm.nih.gov/pubmed/35732815 http://dx.doi.org/10.1038/s41698-022-00282-8

Ejemplares similares

The Effect of Age on Prostate Cancer Survival
por: Clark, Roderick, et al.
Publicado: (2022)

Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin
por: Cybulski, Cezary
Publicado: (2007)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

“Guys Don’t Have Breasts”: The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer
por: Skop, Michelle, et al.
Publicado: (2018)

Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
por: Clark, Roderick, et al.
Publicado: (2022)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

RECQL: a DNA helicase in breast cancer
por: Akbari, Mohammad R., et al.
Publicado: (2015)

Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer
por: Ghiam, Alireza Fotouhi, et al.
Publicado: (2017)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer
por: Akbari, Mohammad R., et al.
Publicado: (2012)

The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada
por: Narod, Steven A., et al.
Publicado: (2021)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis
por: Jayalath, Viranda H., et al.
Publicado: (2022)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

Oral contraceptive use is associated with prostate cancer: an ecological study
por: Margel, David, et al.
Publicado: (2011)

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?
por: Stempa, Klaudia, et al.
Publicado: (2021)

High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival
por: Mahmoodi, Ardalan, et al.
Publicado: (2022)

Inherited NBN Mutations and Prostate Cancer Risk and Survival
por: Rusak, Bogna, et al.
Publicado: (2019)

Common genetic susceptibility to DCIS and invasive ductal carcinoma
por: Sopik, Victoria, et al.
Publicado: (2016)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Critical appraisal of the Spanner™ prostatic stent in the treatment of prostatic obstruction
por: McKenzie, Patrick, et al.
Publicado: (2011)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

The Effects of Serum from Prostate Cancer Patients with Elevated Body Mass Index on Prostate Cancer Cells In Vitro
por: Mora, Benjamin C, et al.
Publicado: (2015)

A narrative review of pelvic lymph node dissection in prostate cancer
por: Cheung, Douglas C., et al.
Publicado: (2020)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Multiple therapeutic and preventive effects of 3,3′-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia
por: Zhang, William Weiben, et al.
Publicado: (2014)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Intraductal carcinoma of the prostate: a critical re-appraisal
por: Varma, Murali, et al.
Publicado: (2019)

Appraising risk in active surveillance of localized prostate cancer
por: Hogden, Anne, et al.
Publicado: (2019)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence
por: Kamdar, Shivani, et al.
Publicado: (2020)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma
por: Liu, G, et al.
Publicado: (2000)

Quality and impact of appraisal for revalidation: the perceptions of London’s responsible officers and their appraisers
por: Griffin, Ann, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_apl0v8ue1e9f44tmfqe2ehko8a